Mineralys Therapeutics Inc (NASDAQ: MLYS) is -1.65% lower on its value in year-to-date trading and has touched a low of $8.24 and a high of $18.38 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MLYS stock was last observed hovering at around $14.32 in the last trading session, with the day’s gains setting it 0.02%.
Currently trading at $14.34, the stock is 1.55% and -3.69% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.02 million and changing 0.14% at the moment leaves the stock 9.41% off its SMA200. MLYS registered 16.49% gain for a year compared to 6-month gain of 57.24%. The firm has a 50-day simple moving average (SMA 50) of $14.944 and a 200-day simple moving average (SMA200) of $13.06765.
The stock witnessed a 6.62% loss in the last 1 month and extending the period to 3 months gives it a 3.31%, and is -2.05% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.84% over the week and 5.21% over the month.
Mineralys Therapeutics Inc (MLYS) has around 51 employees, a market worth around $934.61M and $0.00M in sales. Distance from 52-week low is 74.01% and -21.98% from its 52-week high. The company has generated returns on investments over the last 12 months (-55.19%).
The EPS is expected to grow by 19.87% this year
205.0 institutions hold shares in Mineralys Therapeutics Inc (MLYS), with institutional investors hold 100.19% of the company’s shares. The shares outstanding are 64.88M, and float is at 40.61M with Short Float at 18.88%. Institutions hold 98.73% of the Float.
The top institutional shareholder in the company is CATALYS PACIFIC, LLC with over 9.19 million shares valued at $107.58 million. The investor’s holdings represent 18.629 of the MLYS Shares outstanding. As of 2024-06-30, the second largest holder is SAMSARA BIOCAPITAL, LLC with 5.07 million shares valued at $59.38 million to account for 10.2822 of the shares outstanding. The other top investors are RA CAPITAL MANAGEMENT, L.P. which holds 4.85 million shares representing 9.8285 and valued at over $56.76 million, while TCG CROSSOVER MANAGEMENT, LLC holds 6.4535 of the shares totaling 3.19 million with a market value of $37.27 million.
Mineralys Therapeutics Inc (MLYS) Insider Activity
The most recent transaction is an insider sale by Congleton Jon, the company’s Chief Executive Officer. SEC filings show that Congleton Jon sold 15,884 shares of the company’s common stock on Jul 11 ’25 at a price of $14.51 per share for a total of $0.23 million. Following the sale, the insider now owns 0.85 million shares.
Mineralys Therapeutics Inc disclosed in a document filed with the SEC on Jul 11 ’25 that Levy Adam Scott (CFO and Secretary) sold a total of 10,758 shares of the company’s common stock. The trade occurred on Jul 11 ’25 and was made at $14.45 per share for $0.16 million. Following the transaction, the insider now directly holds 0.21 million shares of the MLYS stock.
Still, SEC filings show that on Jul 14 ’25, Rodman David Malcom (Chief Medical Officer) disposed off 11,366 shares at an average price of $14.59 for $0.17 million. The insider now directly holds 97,907 shares of Mineralys Therapeutics Inc (MLYS).
